Advertisement
Advertisement

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH09-08-0580
Issue: 2010: 103/1 (Jan) pp. 1–249
Pages: 13-28

Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting

A Consensus Document of the European Society of Cardiology Working Group onThrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]

Online Supplementary Material

G. Y. H. Lip, K. Huber (1), F. Andreotti (2), H. Arnesen (3), K. J. Airaksinen (4), T. Cuisset (5), P. Kirchhof (6), F. Marín (7)
(1) 3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria; (2) Institute of Cardiology, Gemelli University Hospital, Rome, Italy; (3) Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway; (4) Department of Medicine, Turku University Hospital, Turku, Finland; (5) Department of Cardiology, CHU Timone, Marseille, France; (6) Department of Cardiology and Angiology, Universitätsklinikum Münster, Münster, Germany; (7) Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Ctra Madrid-Cartagena s/n, Murcia, Spain

Keywords

stenting, Acute coronary syndrome, percutaneous coronary intervention, warfarin, antithrombotic therapy, Arial fibrillation

Summary

There remains uncertainty over optimal antithrombotic management strategy for patients with atrial fibrillation (AF) presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Clinicians need to balance the risk of stroke and thromboembolism against the risk of recurrent cardiac ischaemia and/or stent thrombosis, and the risk of bleeding. This consensus document comprehensively reviews the published evidence and presents a consensus statement on a ‘best practice’ antithrombotic therapy guideline for the management of antithrombotic therapy in such AF patients.

You may also be interested in...

1.
H. Hölschermann

Hämostaseologie 2007 27 5: 319-325

2.
H. Hölschermann

Hämostaseologie 2006 26 2: 106-113

3.
T. Wichter

Hämostaseologie 2006 26 2: 138-146